This study wants to test the safety and how well it works of BHV-3000 versus dummy treatment (placebo) in the acute treatment of moderate or severe migraine in children and adolescents.
NCT04649242 · Official ClinicalTrials.gov record · Pfizer
The goal of this clinical trial is to evaluate whether a low-glutamate diet can improve migraine symptoms in adults with migraine and to explore possible biological changes associated with dietary improvement. The study focuses on whether reducing dietary glutamate intake may influence processes involved in migraine, such as brain excitation, inflammation, and oxidative stress.
Official registry: https://clinicaltrials.gov/study/NCT07360405 · American University · enrollment listed as 40
This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
If you join, the listed intervention(s) are Dietary training. The registry lists allocation as randomized. The goal of this clinical trial is to evaluate whether a low-glutamate diet can improve migraine symptoms in adults with migraine and to explore possible biological changes associated with dietary improvement.
They plan to enroll about 40 people at Washington D.C.. Taking part typically means following a program (exercise, therapy, diet, or an app) plus check-ins.
Diet-Based Treatment for Migraine Relief
Interventions: Dietary training
Primary outcome (registry wording): Migraine days
Kathleen Holton
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
This study wants to test the safety and how well it works of BHV-3000 versus dummy treatment (placebo) in the acute treatment of moderate or severe migraine in children and adolescents.
NCT04649242 · Official ClinicalTrials.gov record · Pfizer
This study wants to test the long-term safety of rimegepant in the acute treatment of migraine in children and adolescents (≥ 6 to \< 18 years of age).
NCT04743141 · Official ClinicalTrials.gov record · Pfizer
To find out if eptinezumab is better than dummy treatment (placebo) (normal saline solution) in lowering the number of days with migraine in young people ages 12 to 17 with chronic migraine.
NCT04965675 · Official ClinicalTrials.gov record · H. Lundbeck A/S
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary